Limits...
Biochanin A Modulates Cell Viability, Invasion, and Growth Promoting Signaling Pathways in HER-2-Positive Breast Cancer Cells.

Sehdev V, Lai JC, Bhushan A - J Oncol (2010)

Bottom Line: Overexpression of HER-2 receptor is associated with poor prognosis and aggressive forms of breast cancer.Subsequently cell viability assay, western blotting and zymography were carried out.Biochanin A did not inhibit MCF-10A and NIH-3T3 cell viability.

View Article: PubMed Central - PubMed

Affiliation: Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy Idaho, Biomedical Research Institute, Idaho State University, Pocatello, ID 83209, USA.

ABSTRACT
Overexpression of HER-2 receptor is associated with poor prognosis and aggressive forms of breast cancer. Scientific literature indicates a preventive role of isoflavones in cancer. Since activation of HER-2 receptor initiates growth-promoting events in cancer cells, we studied the effect of biochanin A (an isoflavone) on associated signaling events like receptor activation, downstream signaling, and invasive pathways. HER-2-positive SK-BR-3 breast cancer cells, MCF-10A normal breast epithelial cells, and NIH-3T3 normal fibroblast cells were treated with biochanin A (2-100 muM) for 72 hours. Subsequently cell viability assay, western blotting and zymography were carried out. The data indicate that biochanin A inhibits cell viability, signaling pathways, and invasive enzyme expression and activity in SK-BR-3 cancer cells. Biochanin A did not inhibit MCF-10A and NIH-3T3 cell viability. Therefore, biochanin A could be a unique natural anticancer agent which can selectively target cancer cells and inhibit multiple signaling pathways in HER-2-positive breast cancer cells.

No MeSH data available.


Related in: MedlinePlus

Effect of biochanin A on MT-MMP1 protein expression. (a) SK-BR-3 breast cancer cells were seeded in a T-75 flask in RPMI-1640 cell culture media (10% FBS). Following 72 hours of treatment with biochanin A (2–50 μM) MT-MMP1 protein expression was evaluated. Our data indicate reduced MT-MMP-1 expression at 10 and 50 μM biochanin A (Biochanin A: 10 μM  → 19.22 ± 9.93; 50 μM  → 2.39 ± 2.30; P < .05). C: control or no treatment; DMSO: vehicle  (Statistical analysis: One-way Anova, n = 3, *P < .05). (b) Representative blot for MT-MMP-1 protein expression.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2821773&req=5

fig8: Effect of biochanin A on MT-MMP1 protein expression. (a) SK-BR-3 breast cancer cells were seeded in a T-75 flask in RPMI-1640 cell culture media (10% FBS). Following 72 hours of treatment with biochanin A (2–50 μM) MT-MMP1 protein expression was evaluated. Our data indicate reduced MT-MMP-1 expression at 10 and 50 μM biochanin A (Biochanin A: 10 μM  → 19.22 ± 9.93; 50 μM  → 2.39 ± 2.30; P < .05). C: control or no treatment; DMSO: vehicle (Statistical analysis: One-way Anova, n = 3, *P < .05). (b) Representative blot for MT-MMP-1 protein expression.

Mentions: MT-MMP1 or MMP-14 is required for activation of matrix metalloproteases (MMPs) [52]. Western blotting data (Figure 8) with MT-MMP1 specific antibody indicate inhibition of MT-MMP1 enzyme expression in SK-BR-3 cells treated with 10 (19.22 ± 9.93; P < .05) and 50 μM (2.39 ± 2.30; P < .05) biochanin A (Biochanin A: 10 μM  → 19.22 ± 9.93; 50 μM  → 2.39 ± 2.30; P < .05) (Figure 8). Biochanin A-mediated inhibition of MMP-9 enzyme activity and MT-MMP1 protein expression suggests that biochanin A can block invasion promoting signaling mechanisms in SK-BR-3 breast cancer cells.


Biochanin A Modulates Cell Viability, Invasion, and Growth Promoting Signaling Pathways in HER-2-Positive Breast Cancer Cells.

Sehdev V, Lai JC, Bhushan A - J Oncol (2010)

Effect of biochanin A on MT-MMP1 protein expression. (a) SK-BR-3 breast cancer cells were seeded in a T-75 flask in RPMI-1640 cell culture media (10% FBS). Following 72 hours of treatment with biochanin A (2–50 μM) MT-MMP1 protein expression was evaluated. Our data indicate reduced MT-MMP-1 expression at 10 and 50 μM biochanin A (Biochanin A: 10 μM  → 19.22 ± 9.93; 50 μM  → 2.39 ± 2.30; P < .05). C: control or no treatment; DMSO: vehicle  (Statistical analysis: One-way Anova, n = 3, *P < .05). (b) Representative blot for MT-MMP-1 protein expression.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2821773&req=5

fig8: Effect of biochanin A on MT-MMP1 protein expression. (a) SK-BR-3 breast cancer cells were seeded in a T-75 flask in RPMI-1640 cell culture media (10% FBS). Following 72 hours of treatment with biochanin A (2–50 μM) MT-MMP1 protein expression was evaluated. Our data indicate reduced MT-MMP-1 expression at 10 and 50 μM biochanin A (Biochanin A: 10 μM  → 19.22 ± 9.93; 50 μM  → 2.39 ± 2.30; P < .05). C: control or no treatment; DMSO: vehicle (Statistical analysis: One-way Anova, n = 3, *P < .05). (b) Representative blot for MT-MMP-1 protein expression.
Mentions: MT-MMP1 or MMP-14 is required for activation of matrix metalloproteases (MMPs) [52]. Western blotting data (Figure 8) with MT-MMP1 specific antibody indicate inhibition of MT-MMP1 enzyme expression in SK-BR-3 cells treated with 10 (19.22 ± 9.93; P < .05) and 50 μM (2.39 ± 2.30; P < .05) biochanin A (Biochanin A: 10 μM  → 19.22 ± 9.93; 50 μM  → 2.39 ± 2.30; P < .05) (Figure 8). Biochanin A-mediated inhibition of MMP-9 enzyme activity and MT-MMP1 protein expression suggests that biochanin A can block invasion promoting signaling mechanisms in SK-BR-3 breast cancer cells.

Bottom Line: Overexpression of HER-2 receptor is associated with poor prognosis and aggressive forms of breast cancer.Subsequently cell viability assay, western blotting and zymography were carried out.Biochanin A did not inhibit MCF-10A and NIH-3T3 cell viability.

View Article: PubMed Central - PubMed

Affiliation: Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy Idaho, Biomedical Research Institute, Idaho State University, Pocatello, ID 83209, USA.

ABSTRACT
Overexpression of HER-2 receptor is associated with poor prognosis and aggressive forms of breast cancer. Scientific literature indicates a preventive role of isoflavones in cancer. Since activation of HER-2 receptor initiates growth-promoting events in cancer cells, we studied the effect of biochanin A (an isoflavone) on associated signaling events like receptor activation, downstream signaling, and invasive pathways. HER-2-positive SK-BR-3 breast cancer cells, MCF-10A normal breast epithelial cells, and NIH-3T3 normal fibroblast cells were treated with biochanin A (2-100 muM) for 72 hours. Subsequently cell viability assay, western blotting and zymography were carried out. The data indicate that biochanin A inhibits cell viability, signaling pathways, and invasive enzyme expression and activity in SK-BR-3 cancer cells. Biochanin A did not inhibit MCF-10A and NIH-3T3 cell viability. Therefore, biochanin A could be a unique natural anticancer agent which can selectively target cancer cells and inhibit multiple signaling pathways in HER-2-positive breast cancer cells.

No MeSH data available.


Related in: MedlinePlus